Topics & People

A new startup co-founded by former OpenAI chief scientist Ilia Sutskever, Daniel Gross, and Daniel Levy. Its stated goal is to focus exclusively on developing a safe superintelligence as its first product.

The European Union, functioning as a strict regulatory body enforcing privacy standards upon technology companies.

A strategy of combining multiple products or services into a single package. This is discussed as a potential solution for the streaming industry's churn problem, with examples like YouTube TV, Apple One, and The New York Times' digital subscription.

A significant decrease in job postings for software developers, down 80% from its peak and below pre-COVID levels, attributed to economic weakness and the end of the ZIRP era rather than AI-driven job replacement.

The concept of the Democratic Party replacing Joe Biden as their presidential nominee after the primaries have concluded, due to his poor debate performance and concerns about his fitness to serve.

The first presidential debate of the 2024 election cycle, which featured a new format with muted microphones and no audience. Joe Biden's performance was widely seen as a major failure, shifting the political landscape.

The US regulatory body that grants monopolies on medical therapies, driving up costs for treatments like Moderna's cancer vaccine.

Pharmaceutical company that developed breakthrough GLP-1 drugs, seeing massive stock growth.

A class of widely prescribed anti-depressants (Selective Serotonin Reuptake Inhibitors). GLP-1 drugs are being explored as a potential alternative or adjunct for improving psychological health, representing a potential disruption.

A 2011 US law that changed the patent system from 'first to invent' to 'first to file'. This change incentivizes companies to file patents as early as possible, which inadvertently exposes the invention to 'patent hacking' by competitors.

An upcoming pill version of the GLP-1 drug from Eli Lilly, expected next year. This format aims to improve convenience and accessibility, with a primary goal of getting it reimbursed by insurance.

A blockbuster cancer drug from Merck whose quarterly sales were surpassed by Eli Lilly's Tirzepatide, marking a major shift in the pharmaceutical market.